Overview of (pre)treatment effects: different LY404039 experimental protocols in comparison with the vehicle + saline condition
Percentage increase or decrease of activity (± S.E.M.).
| LY404039 | Versus Vehicle of LY404039 and Saline | |||
|---|---|---|---|---|
| Treatment | Vehicle + Memantine | Vehicle + Ketamine | LY404039 + Memantine | LY404039 + Ketamine |
| % | ||||
| Caudate putamen | 32.0 ± 8.7 | 14.6 ± 7.0 | −5.3 ± 5.6 | −21.2 ± 5.0 |
| Cingulate cortex | 47.6 ± 10.9 | 20.2 ± 9.1 | −6.7 ± 6.2 | −27.1 ± 5.7 |
| Frontal cortex | 50.1 ± 12.1 | 22.4 ± 9.8 | −0.9 ± 7.3 | −26.3 ± 5.9 |
| Medial prefrontal cortex | 43.5 ± 9.6 | 18.8 ± 8.6 | −5.9 ± 5.9 | −25.0 ± 5.4 |
| Motor cortex | 47.3 ± 11.9 | 20.9 ± 9.5 | −0.3 ± 7.1 | −23.8 ± 6.1 |
| Parietal cortex | 42.2 ± 12.1 | 17.2 ± 9.1 | −1.7 ± 7.1 | −21.7 ± 5.6 |
| Hippocampus (AD) | 32.3 ± 8.8 | 13.7 ± 6.1 | −8.0 ± 4.8 | −20.7 ± 4.6 |
| Thalamus | 31.0 ± 8.9 | 13.2 ± 6.9 | −10.9 ± 5.2 | −23.5 ± 4.5 |
AD, anterodorsal.